CREATE Medicines Secures $122M to Advance CAR-T Therapies for Solid Tumors and Autoimmune Diseases

CREATE Medicines, a biotechnology company developing innovative CAR-T therapies, has secured $122 million in new funding to advance its pipeline of first-in-class treatments through human trials. The company, formerly known as Myeloid Therapeutics, was co-founded by renowned oncologist and author Dr. Siddhartha Mukherjee to pioneer therapies using myeloid cells—immune agents designed to more effectively target solid tumors.

From Myeloid Therapeutics to CREATE Medicines: A Strategic Rebrand

Last year, the company underwent a strategic rebranding, transitioning from Myeloid Therapeutics to CREATE Medicines. This change reflected the company’s expanded mission beyond solid tumor treatment. Like many oncology-focused CAR-T companies, CREATE has broadened its research focus to include autoimmune diseases, aiming to leverage its proprietary myeloid cell technology across multiple therapeutic areas.

Funding Round Details and Investors

The $122 million funding round was led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, among other investors. According to an exclusive report by STAT, this capital infusion will accelerate the development of CREATE’s CAR-T candidates, positioning the company to advance its lead programs into clinical trials.

CAR-T Therapy: A Breakthrough in Cancer and Autoimmune Treatment

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary approach that genetically modifies a patient’s T-cells to recognize and attack cancer cells. While CAR-T therapies have shown remarkable success in treating certain blood cancers, their application to solid tumors has proven more challenging due to the tumor microenvironment. CREATE Medicines aims to overcome this hurdle by utilizing myeloid cells, which are believed to offer superior targeting and persistence in solid tumor environments.

In addition to oncology, the company is exploring the potential of its myeloid-based CAR-T therapies in autoimmune diseases, where immune system dysregulation plays a key role. This dual focus underscores CREATE’s ambition to address some of the most complex and life-threatening medical conditions.

Key Takeaways

• Company Evolution: Formerly Myeloid Therapeutics, CREATE Medicines rebranded to reflect its expanded therapeutic focus.
• Leadership: Co-founded by Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning oncologist and bestselling author.
• Funding: $122 million raised from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and others.
• Pipeline Expansion: Transitioned from solid tumor therapies to include autoimmune disease research.
• Technology: Utilizes myeloid cell-based CAR-T therapies to enhance targeting of solid tumors and autoimmune conditions.